naproxen has been researched along with niacin in 13 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (niacin) | Trials (niacin) | Recent Studies (post-2010) (niacin) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 11,974 | 462 | 1,488 |
| Protein | Taxonomy | naproxen (IC50) | niacin (IC50) |
|---|---|---|---|
| Cholesteryl ester transfer protein | Homo sapiens (human) | 0.14 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.14 | |
| Hydroxycarboxylic acid receptor 2 | Homo sapiens (human) | 0.1726 | |
| Hydroxycarboxylic acid receptor 2 | Mus musculus (house mouse) | 0.14 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baert, B; Beetens, J; Bodé, S; De Spiegeleer, B; Deconinck, E; Lambert, J; Slegers, G; Slodicka, M; Stoppie, P; Van Gele, M; Vander Heyden, Y | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Ando, H; Furuuchi, S; Harigaya, S; Sugihara, J; Takashima, K | 1 |
| Cristina, RH; María Jesús, MV; Miguel Ángel, BL; Rut, FT | 1 |
| Bello-López, MÁ; López-Pérez, G; Martín-Valero, MJ; Román-Hidalgo, C | 1 |
1 review(s) available for naproxen and niacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for naproxen and niacin
| Article | Year |
|---|---|
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
Topics: Anti-Inflammatory Agents; Cell Membrane Permeability; Cluster Analysis; Drug Evaluation, Preclinical; Humans; Models, Biological; Predictive Value of Tests; Quantitative Structure-Activity Relationship; Regression Analysis; Skin; Skin Absorption | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Studies on intestinal lymphatic absorption of drugs. II. Glyceride prodrugs for improving lymphatic absorption of naproxen and nicotinic acid.
Topics: Animals; Cholesterol; Chromatography, Thin Layer; Fatty Acids, Nonesterified; Glycerides; Intestinal Absorption; Lymphatic System; Male; Models, Biological; Naproxen; Niacin; Prodrugs; Rats; Rats, Inbred Strains; Triglycerides | 1988 |
Use of Polymer Inclusion Membranes (PIMs) as support for electromembrane extraction of non-steroidal anti-inflammatory drugs and highly polar acidic drugs.
Topics: Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Cellulose; Electrochemical Techniques; Hippurates; Ibuprofen; Ketoprofen; Membranes, Artificial; Naproxen; Niacin; ortho-Aminobenzoates; Quaternary Ammonium Compounds; Salicylic Acid | 2018 |
Chitosan tailor-made membranes as biopolymeric support for electromembrane extraction.
Topics: Amoxicillin; Biopolymers; Chitosan; Electrochemical Techniques; Hippurates; Humans; Ibuprofen; Ketoprofen; Naproxen; Niacin; ortho-Aminobenzoates; Salicylic Acid | 2019 |